Get the Stockscreener App
5.49
3.00%
0.16
After Hours:
5.44
-0.05
-0.91%
Compass Therapeutics Inc stock is traded at $5.49, with a volume of 1.26M.
It is up +3.00% in the last 24 hours and down -6.79% over the past month.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
See More
Previous Close:
$5.33
Open:
$5.42
24h Volume:
1.26M
Relative Volume:
0.57
Market Cap:
$988.68M
Revenue:
$850.00K
Net Income/Loss:
$-66.49M
P/E Ratio:
-12.66
EPS:
-0.4336
Net Cash Flow:
$-49.17M
1W Performance:
+3.20%
1M Performance:
-6.79%
6M Performance:
+57.31%
1Y Performance:
+153.58%
1-Day Range:
$5.39
$5.56
1-Week Range:
$4.87
$5.56
52-Week Range:
$1.33
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
5.49 | 959.87M | 850.00K | -66.49M | -49.17M | -0.4336 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-26 | Initiated | Craig Hallum | Buy |
| Jan-05-26 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Canaccord Genuity | Buy |
| Dec-03-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from Guggenheim - MarketBeat
Compass Therapeutics: Potential Here, But Patience Required (NASDAQ:CMPX) - Seeking Alpha
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Compass Therapeutics Inc stock go up in YEARWeekly Trade Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Compass Therapeutics, Inc.Common Stock (NQ: CMPX - The Chronicle-Journal
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Here's why Compass Therapeutics, Inc. (CMPX) is a great momentum stock to buy - MSN
Compass Therapeutics Sees Major Institutional Investment Boost - National Today
Compass Therapeutics, Inc. $CMPX Stock Position Lifted by Suvretta Capital Management LLC - MarketBeat
Cantor Fitzgerald Maintains Overweight on CMPX (Compass Therapeutics, Inc.), Mar 2026 - Meyka
Is Compass Therapeutics' (CMPX) New ESOP Shelf Offering Reframing Its Equity-Funded R&D Strategy? - Sahm
Compass Therapeutics Inc celebrates women leadership driving innovation in science and therapy development - Traders Union
Compass Therapeutics stock rating reaffirmed at Citizens on trial progress By Investing.com - Investing.com Canada
What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology Strategy - Yahoo Finance
HC Wainwright Has Positive Estimate for CMPX FY2026 Earnings - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX) - The Globe and Mail
What is HC Wainwright's Estimate for CMPX Q1 Earnings? - MarketBeat
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update - Sahm
Jefferies raises Compass Therapeutics stock price target on trial progress By Investing.com - Investing.com South Africa
Jefferies raises Compass Therapeutics stock price target on trial progress - Investing.com
Compass Therapeutics stock holds Outperform at William Blair ahead of trial data - Investing.com Canada
Raymond James reiterates Compass Therapeutics stock Outperform rating By Investing.com - Investing.com Canada
Raymond James reiterates Compass Therapeutics stock Outperform rating - Investing.com
Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Compass Therapeutics' Q4 Net Loss Narrows - marketscreener.com
Earnings Flash (CMPX) Compass Therapeutics Posts Q4 Net Loss $0.09 a Share, vs. FactSet Est of $0.09 Loss - marketscreener.com
Compass Therapeutics' 2025 net loss widens as R&D costs jump - TradingView
Compass Therapeutics 10-K: $0.0M Revenue, $(0.42) EPS on $(66.5)M Net Loss - TradingView
Compass Therapeutics, NAQ receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
How Palo Alto’s New Stake and Rising Institutional Ownership At Compass Therapeutics (CMPX) Has Changed Its Investment Story - simplywall.st
Assessing Compass Therapeutics (CMPX) Valuation As CTX-009 Gains Attention In Biliary Tract Cancer Market - Yahoo Finance
Monashee Investment Management Boosts Stake in Compass Therapeutics - National Today
Signal Recap: Does Compass Therapeutics Inc have a competitive edgeQuarterly Performance Summary & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Investment Firm Bets Big on Compass Therapeutics, Adds 2.5 Million Shares - National Today
Monashee Investment Management LLC Has $4.38 Million Stake in Compass Therapeutics, Inc. $CMPX - MarketBeat
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a 130% Potential Upside in Biotech - DirectorsTalk Interviews
Compass Therapeutics earnings on deck as pivotal cancer data looms By Investing.com - Investing.com Canada
Compass Therapeutics earnings on deck as pivotal cancer data looms - Investing.com
Compass Therapeutics Inc. expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Zacks.com Spotlights Orla Mining, FIGS, and Compass Therapeutics - Intellectia AI
Is Compass Therapeutics Inc. stock forming a cup and handleJuly 2025 Retail & Reliable Entry Point Trade Alerts - mfd.ru
Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know - TipRanks
Compass Therapeutics (CMPX) to Release Quarterly Earnings on Thursday - MarketBeat
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):